Comprehensive medication guide to Trijardy XR including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$100 copay with commercial insurance; manufacturer co-pay card may reduce cost to $0/month for eligible commercially insured patients; typically Tier 4 on Medicare Part D with prior authorization required.
Estimated Cash Pricing
$350–$750 per month retail for brand Trijardy XR (no generic available as of 2026); as low as $356 with GoodRx or $233 for 60 tablets with SingleCare coupons.
Medfinder Findability Score
62/100
Summarize with AI
On this page
Trijardy XR is a prescription oral tablet that combines three diabetes medications into a single once-daily extended-release dose: empagliflozin (an SGLT2 inhibitor), linagliptin (a DPP-4 inhibitor), and metformin hydrochloride extended-release (a biguanide). It was FDA-approved in 2020 and is manufactured by Boehringer Ingelheim.
Trijardy XR is used as an adjunct to diet and exercise to improve blood sugar (glycemic) control in adults with type 2 diabetes mellitus. The empagliflozin component also carries an FDA-approved indication to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Trijardy XR is not approved for type 1 diabetes, patients on dialysis, patients with eGFR below 30, or anyone under 18 years old. It is the only FDA-approved triple fixed-dose combination of an SGLT2 inhibitor, DPP-4 inhibitor, and biguanide extended-release in a single tablet.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Trijardy XR lowers blood sugar through three distinct, complementary mechanisms. Empagliflozin blocks the SGLT2 protein in the kidneys, which normally reabsorbs glucose from urine back into the bloodstream. By inhibiting this transporter, empagliflozin causes excess glucose to be excreted through urine, lowering blood sugar without relying on insulin. This mechanism also reduces blood pressure and fluid burden on the heart, contributing to cardiovascular protection.
Linagliptin inhibits the enzyme DPP-4, which normally breaks down incretin hormones (GLP-1 and GIP) within minutes of their release. By protecting these hormones, linagliptin enhances post-meal insulin secretion and suppresses glucagon — the hormone that causes the liver to release glucose. Because this effect is glucose-dependent, linagliptin carries a low risk of hypoglycemia on its own.
Metformin extended-release primarily suppresses excessive hepatic glucose production by activating AMPK, an enzyme that acts as a cellular energy sensor. It also reduces glucose absorption from the intestines and improves peripheral insulin sensitivity. The extended-release formulation releases metformin slowly throughout the day, reducing the gastrointestinal side effects associated with immediate-release metformin.
10mg/5mg/1000mg — extended-release tablet
One tablet once daily in the morning with a meal
25mg/5mg/1000mg — extended-release tablet
One tablet once daily in the morning with a meal (maximum empagliflozin dose)
5mg/2.5mg/1000mg — extended-release tablet
Two tablets once daily in the morning with a meal
12.5mg/2.5mg/1000mg — extended-release tablet
Two tablets once daily in the morning with a meal (maximum empagliflozin dose)
Trijardy XR is not in an active FDA-declared shortage as of 2026, but patients regularly encounter difficulty finding it at their local pharmacy. As a brand-name-only product (no generic available), only Boehringer Ingelheim manufactures it. Combined with four different strength combinations and high acquisition cost, many pharmacies don't keep it as standing inventory.
The empagliflozin component has seen significantly increased demand due to expanded FDA indications (heart failure, CKD), which creates supply pressure on all empagliflozin-containing products including Trijardy XR. Patients may need to check multiple pharmacies to find their specific strength, and availability can vary by region, pharmacy type, and time of month.
Use medfinder to check which pharmacies near you have Trijardy XR in stock right now. medfinder contacts pharmacies in your area and texts you results — so you can skip the hold music and find your medication faster.
Trijardy XR is not a controlled substance and is not restricted to specific specialists. Any licensed healthcare provider with prescribing authority can prescribe it for appropriate patients with type 2 diabetes. No DEA special licensing or special prescription pads are required.
Providers who commonly prescribe Trijardy XR include:
Telehealth prescribing is available for Trijardy XR since it is not a controlled substance. Most diabetes-focused telehealth platforms (Teladoc, Ro, and others) can prescribe it after reviewing recent lab results (A1C and eGFR) and confirming a type 2 diabetes diagnosis.
No. Trijardy XR is not a controlled substance and has no DEA schedule. It contains no stimulants, opioids, or other scheduled ingredients. This means Trijardy XR can be prescribed by any licensed prescriber with prescribing authority (including primary care physicians, nurse practitioners, and physician assistants) without the special licensing required for controlled substances.
Prescriptions for Trijardy XR can be sent electronically, called in by phone, or given as a written prescription. There are no restrictions on the number of refills, and it can be filled through mail-order pharmacy for 90-day supplies. Patients do not need to visit a specialty pharmacy or present ID beyond standard pharmacy identification requirements.
These side effects have been reported by 2% or more of patients in clinical trials:
Seek immediate medical attention if you experience any of the following:
Know what you need? Skip the search.
Jardiance (empagliflozin)
Standalone SGLT2 inhibitor; same cardiovascular benefits as Trijardy XR's empagliflozin component. May be prescribed with separate linagliptin and metformin.
Synjardy XR (empagliflozin + metformin ER)
Two-drug fixed-dose combination of empagliflozin and extended-release metformin. Add separate linagliptin to replicate Trijardy XR's full effect.
Glyxambi (empagliflozin + linagliptin)
Fixed-dose combination of empagliflozin and linagliptin without metformin. Add generic metformin ER for full Trijardy XR equivalence.
Janumet XR (sitagliptin + metformin ER)
DPP-4 inhibitor plus metformin ER combination; generic available (lower cost). Lacks SGLT2 inhibitor component and cardiovascular indication.
Farxiga (dapagliflozin)
Alternative SGLT2 inhibitor; FDA-approved for T2DM, HFrEF, and CKD. Often better stocked than empagliflozin products. Can be combined with separate DPP-4 inhibitor and metformin.
Prefer Trijardy XR? We can find it.
ACE inhibitors (benazepril, captopril, lisinopril)
majorLinagliptin increases risk of angioedema with ACE inhibitors — potentially life-threatening swelling. Avoid combination or use ARB instead.
Strong CYP3A4 inducers (apalutamide, rifampin, carbamazepine)
majorSignificantly reduce linagliptin blood levels, reducing effectiveness. Avoid or use alternative DPP-4 inhibitor.
Iodinated contrast media
majorHold Trijardy XR before and 48 hours after contrast imaging (eGFR < 60, liver disease, heart failure, or alcoholism). Restart only after confirming stable kidney function.
Insulin and sulfonylureas
moderateAdditive hypoglycemia risk. Reduce insulin or sulfonylurea dose when adding Trijardy XR.
Diuretics (furosemide, hydrochlorothiazide)
moderateAdditive diuretic effect increases risk of volume depletion, dehydration, and hypotension. Monitor blood pressure and kidney function.
Alcohol
majorIncreases risk of lactic acidosis (metformin component) and diabetic ketoacidosis (empagliflozin component). Avoid or significantly limit alcohol.
Cimetidine (Tagamet)
moderateMay increase metformin plasma levels by reducing renal clearance. Monitor for metformin toxicity symptoms.
Trijardy XR represents a significant advancement in type 2 diabetes management by combining three complementary mechanisms into a single once-daily tablet. For patients with type 2 diabetes — particularly those with established cardiovascular disease or at high cardiovascular risk — it offers the convenience of combination therapy along with the proven cardiovascular benefits of empagliflozin.
The main challenges with Trijardy XR are cost and availability. As a brand-name-only medication with no generic, it carries a high price tag. Manufacturer savings programs, prescription discount cards, and patient assistance programs can significantly reduce what patients pay. Patients should explore all options before concluding Trijardy XR is unaffordable.
When your pharmacy is out of stock, use medfinder to find which pharmacies near you have Trijardy XR available. medfinder contacts pharmacies in your area and texts you results — making it the fastest way to locate your medication without spending time on hold.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini